STOCK TITAN

Guardant Health (GH) Chief Legal Officer sells 20,000 shares in open-market trades

Filing Impact
(Very High)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

Guardant Health, Inc. Chief Legal Officer John G. Saia reported open-market sales of a total of 20,000 shares of common stock on May 20, 2026. The shares were sold in three separate transactions at weighted average prices around $105–$107 per share, each executed across multiple trades within narrow intraday price ranges. These transactions reduce his direct holdings but he continues to own Guardant Health stock after the sales.

Positive

  • None.

Negative

  • None.
Insider Saia John G.
Role Chief Legal Officer
Sold 20,000 shs ($2.13M)
Type Security Shares Price Value
Sale Common Stock 5,632 $105.3433 $593K
Sale Common Stock 7,187 $106.712 $767K
Sale Common Stock 7,181 $107.2269 $770K
Holdings After Transaction: Common Stock — 60,318 shares (Direct, null)
Footnotes (1)
  1. Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $105.00 to $105.86. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range. Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $106.00 to $106.99. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range. Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $107.00 to $107.96. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range.
Total shares sold 20,000 shares Aggregate insider sales on May 20, 2026
Sale block 1 7,181 shares at $107.2269 Open-market sale, weighted average price
Sale block 2 7,187 shares at $106.7120 Open-market sale, weighted average price
Sale block 3 5,632 shares at $105.3433 Open-market sale, weighted average price
Price range block 1 $107.00–$107.96 Footnote F3 intraday trade range
Price range block 2 $106.00–$106.99 Footnote F2 intraday trade range
Price range block 3 $105.00–$105.86 Footnote F1 intraday trade range
open-market sale financial
"transaction_action: open-market sale"
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
weighted average sales price per share financial
"Represents the weighted average sales price per share."
Common Stock financial
"security_title: Common Stock"
Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.
Form 4 regulatory
"INSIDER FILING DATA (Form 4):"
Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.
transaction code S regulatory
"transaction_code: "S""
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Saia John G.

(Last)(First)(Middle)
3100 HANOVER STREET

(Street)
PALO ALTO CALIFORNIA 94304

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Guardant Health, Inc. [ GH ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
Chief Legal Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
05/20/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock05/20/2026S5,632D$105.3433(1)60,318D
Common Stock05/20/2026S7,187D$106.712(2)53,131D
Common Stock05/20/2026S7,181D$107.2269(3)45,950D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $105.00 to $105.86. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range.
2. Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $106.00 to $106.99. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range.
3. Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $107.00 to $107.96. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range.
Remarks:
/s/ John G. Saia05/22/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Guardant Health (GH) report for John G. Saia?

Guardant Health’s Chief Legal Officer John G. Saia reported selling 20,000 shares of common stock in open-market transactions on May 20, 2026. The Form 4 lists three separate sales at weighted average prices between about $105 and $107 per share.

At what prices were the Guardant Health (GH) insider sales executed?

The reported sales occurred at weighted average prices near $105.34, $106.71, and $107.23 per share. Footnotes explain these were aggregates of multiple trades within narrower ranges between $105.00 and $107.96 on May 20, 2026.

Were the Guardant Health (GH) insider transactions open-market sales?

Yes. Each transaction is coded “S” for sale and described as an open-market or private transaction in common stock. The filing characterizes them as standard open-market sales, not option exercises, gifts, or tax withholdings.

Does John G. Saia still hold Guardant Health (GH) shares after these sales?

Yes. The Form 4 shows that John G. Saia continues to hold Guardant Health common stock directly after the reported transactions. While specific final totals differ by line item, the filing indicates an ongoing equity position in the company.